ATB Cormark Capital Markets Issues Pessimistic Forecast for Tilray Brands (NASDAQ:TLRY) Stock Price

Tilray Brands (NASDAQ:TLRY) had its price objective reduced by equities researchers at ATB Cormark Capital Markets from $9.50 to $9.00 in a note issued to investors on Thursday,BayStreet.CA reports. The brokerage presently has a “sector perform” rating on the stock. ATB Cormark Capital Markets’ price objective indicates a potential upside of 36.88% from the stock’s previous close.

Several other research firms have also recently commented on TLRY. Zacks Research upgraded shares of Tilray Brands from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tilray Brands in a report on Wednesday, January 21st. Wall Street Zen upgraded Tilray Brands from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st. Canaccord Genuity Group started coverage on Tilray Brands in a report on Tuesday, January 27th. They issued a “hold” rating for the company. Finally, Roth Mkm upgraded Tilray Brands from a “neutral” rating to a “buy” rating and set a $10.00 target price on the stock in a research report on Thursday. Three research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Tilray Brands has an average rating of “Hold” and an average target price of $11.20.

Tilray Brands Stock Performance

TLRY stock traded up $0.44 during mid-day trading on Thursday, reaching $6.58. The company had a trading volume of 4,443,714 shares, compared to its average volume of 3,679,706. Tilray Brands has a one year low of $3.51 and a one year high of $23.20. The stock has a market capitalization of $766.03 million, a P/E ratio of -0.30 and a beta of 1.96. The company has a quick ratio of 1.72, a current ratio of 2.81 and a debt-to-equity ratio of 0.19. The stock’s 50-day simple moving average is $7.37 and its two-hundred day simple moving average is $10.25.

Tilray Brands (NASDAQ:TLRY) last released its quarterly earnings results on Wednesday, April 1st. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.10). Tilray Brands had a negative return on equity of 6.35% and a negative net margin of 251.69%.The firm had revenue of $206.73 million for the quarter, compared to the consensus estimate of $201.35 million. During the same quarter in the prior year, the company posted ($0.87) EPS. Research analysts anticipate that Tilray Brands will post -0.2 EPS for the current year.

Institutional Trading of Tilray Brands

Institutional investors have recently made changes to their positions in the stock. Silverlake Wealth Management LLC bought a new position in shares of Tilray Brands in the third quarter valued at approximately $25,000. Oppenheimer & Co. Inc. bought a new stake in Tilray Brands during the third quarter worth approximately $25,000. Unified Investment Management acquired a new stake in Tilray Brands in the third quarter worth approximately $26,000. J.W. Cole Advisors Inc. lifted its position in Tilray Brands by 203.2% in the second quarter. J.W. Cole Advisors Inc. now owns 71,890 shares of the company’s stock worth $30,000 after purchasing an additional 48,177 shares during the period. Finally, Y Intercept Hong Kong Ltd bought a new position in Tilray Brands during the 3rd quarter valued at $30,000. 9.35% of the stock is owned by institutional investors and hedge funds.

Tilray Brands News Summary

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: Record revenue, international cannabis strength and profit improvement — Tilray reported ~11% y/y revenue growth to ~$207M, gross profit expanded and international cannabis/net flower volumes were notably strong, driving the top‑line beat and underpinning the upbeat reaction. GlobeNewswire: Record Q3 Results
• Positive Sentiment: Company reaffirmed full‑year guidance after the quarter, which reduces near‑term uncertainty and helped lift sentiment despite mixed margin commentary. MSN: Reaffirms Outlook
• Positive Sentiment: Analyst upgrade — Roth MKM raised TLRY from Neutral to Buy with a $10 price target, signaling upside from current levels and likely contributing to buying interest. Benzinga: Roth MKM Upgrade
• Positive Sentiment: Strategic M&A and brand partnerships — the company is expanding beverage and global craft beverage presence (BrewDog acquisition referenced in the release) and has a Popsicle RTD partnership that supports beverage pipeline upside over time. InsiderMonkey: Partnership Coverage
• Neutral Sentiment: Earnings call details available — the full transcript and management commentary provide color on margins, international strategy and beverage execution for investors doing deeper due diligence. Seeking Alpha: Earnings Call Transcript
• Neutral Sentiment: Positive screen/social coverage — TLRY is appearing on “best marijuana stocks” lists, which may help retail interest but has uncertain timing/impact. Yahoo: Stock List Inclusion
• Negative Sentiment: EPS miss and continued net loss — TLRY reported a ($0.24) EPS, missing consensus by ~$0.10 despite the revenue beat; the lingering loss keeps profitability concerns front-and-center for analysts. Zacks: Q3 Loss, Revenue Beat
• Negative Sentiment: Beverage segment weakness, margin pressure and competition — investors are focused on beverage execution and rising competition, which helped trigger an intraday selloff despite record revenue. Yahoo: Reasons for Selloff
• Negative Sentiment: Analyst downgrades and lower expectations — some firms cut forecasts or ratings (TD Cowen noted lower expectations; at least one downgrade earlier pushed shares down), adding headwinds to sentiment. AmericanBankingNews: Analyst Actions

About Tilray Brands

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.